← ANALYST RATINGS · TIPRANKS
Aurinia Pharmaceuticals (AUPH): analyst forecast and price target
Analyst consensus
Moderate Buy2 Buy1 Hold0 Sell
Ratings of 3 analysts in the last 3 months12-month forecast
Based on 3 price targets given in the last 3 months, the average target is $18.00, the highest $21.00, the lowest $16.00. The average is +9.0% from the last price of $16.51.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| David Martin PhD★★★★★★★★★★#656 · hits 53% · avg +18.6% | Bloom Burton | $15.00 → $21.00+40.0% | Buy | +27.2% | Upgrade | 20.08.26on TipRanks 08:10 | +7.6%next day −4.0% · 5 days −5.7% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $17.50 | Buy | +6.0% | Reiterated | 20.08.26on TipRanks Aug 19 22:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $17.50 | Buy | +6.0% | Reiterated | 20.08.26on TipRanks Aug 19 22:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $17.00 → $17.50+2.9% | Buy | +6.0% | Reiterated | 20.08.26on TipRanks Aug 19 22:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $16.50 → $17.00+3.0% | Buy | +3.0% | Upgrade | 20.08.26on TipRanks Aug 19 22:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $17.50 | Buy | +6.0% | Reiterated | 20.08.26on TipRanks Aug 19 22:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $17.50 | Buy | +6.0% | Reiterated | 20.08.26on TipRanks Aug 19 22:05 | — | |
| Stacy Ku★★★★★★★★★★#2387 · hits 50% · avg +9.3% | TD Cowen | $17.00 | Buy | +3.0% | Reiterated | 19.08.26on TipRanks Aug 20 05:45 | +5.5%next day +7.6% · 5 days +2.7% | ↗ |
| Douglas Miehm★★★★★★★★★★#2559 · hits 51% · avg +5.3% | RBC Capital | $15.00 → $16.00+6.7% | Hold | −3.1% | Reiterated | 07.08.26on TipRanks 07:06 | −2.3%next day −2.5% · 5 days −2.8% | ↗ |
| Arthur He CFA★★★★★★★★★★#323 · hits 58% · avg +36.5% | H.C. Wainwright | $17.00 | Buy | +3.0% | Reiterated | 27.02.26on TipRanks 06:35 | +1.9%next day +0.2% · 5 days +3.0% | ↗ |
| Joseph Schwartz★★★★★★★★★★#135 · hits 54% · avg +31.9% | Leerink Partners | $16.00 | Hold | −3.1% | Downgrade | 03.12.25on TipRanks 07:55 | −6.6%next day +2.6% · 5 days +3.2% | ↗ |
| Maury Raycroft★★★★★★★★★★#1326 · hits 44% · avg +12.0% | Jefferies | $10.00 → $21.00+110.0% | Buy | +27.2% | Upgrade | 07.11.25on TipRanks 06:20 | +4.6%next day +0.4% · 5 days +4.9% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Aurinia Pharmaceuticals
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $18.00 at a price of $16.20 (+11.1%); now: $18.00 at $16.51 (+9.0%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 2 | 1 | 3 | 5 | 5 | 3 |
| Hold | 3 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 29.10.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $0.22 (from $0.21 to $0.25). Last quarter: $0.28.
Sales
Next quarter’s sales estimate — $84M (from $80M to $87M). Last quarter: $83M.
Best top-analyst consensus in the sector · Healthcare
About Aurinia Pharmaceuticals
- CEO: Kevin C. Tang
- Employees: 128
- #140, 14315 – 118 Avenue, Edmonton, AB, T5L 4S6, CA
- www.auriniapharma.com
Aurinia Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical company, specializing in the development and commercialization of innovative therapies. Its core mission is to address a variety of diseases for which current medical solutions are inadequate, serving patient populations across the United States and internationally. The company's flagship product is LUPKYNIS, an approved treatment designed for adult individuals suffering from active lupus nephritis. Furthermore, Aurinia maintains a strategic collaboration and licensing agreement with Otsuka Pharmaceutical Co., Ltd. The firm's main corporate office is located in Victoria, Canada.
Data from the stock’s TipRanks forecast page, read 139 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗